Cormac Devlin (Dún Laoghaire, Fianna Fail)
Link to this: Individually | In context

665. To ask the Minister for Health to report on the engagement to date between her Department, the HSE and the manufacturer of the Omnipod 5 tubeless hybrid closed-loop insulin delivery system regarding its introduction to the Irish market; if a pricing and reimbursement application has been submitted under the Health (Pricing and Supply of Medical Goods) Act 2013; and if she will make a statement on the matter. [65089/25]

Jennifer Carroll MacNeill (Dún Laoghaire, Fine Gael)
Link to this: Individually | In context

Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for decisions on the pricing and reimbursement of medicines and medical devices; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.

Cormac Devlin (Dún Laoghaire, Fianna Fail)
Link to this: Individually | In context

666. To ask the Minister for Health if the HSE, NCPE or her Department have undertaken, or plan to undertake, a clinical and cost-effectiveness assessment of the Omnipod 5 tubeless hybrid closed-loop insulin pump system, having regard to its availability and funded use in the UK and other EU member states; if so, to outline the status and expected timelines for a decision; and if she will make a statement on the matter. [65090/25]

Jennifer Carroll MacNeill (Dún Laoghaire, Fine Gael)
Link to this: Individually | In context

Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for decisions on the pricing and reimbursement of medicines and medical devices; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.

Cormac Devlin (Dún Laoghaire, Fianna Fail)
Link to this: Individually | In context

667. To ask the Minister for Health her views on the potential role of the Omnipod 5 tubeless hybrid closed-loop insulin system in expanding patient choice for people with type 1 diabetes, including children, people with disabilities, needle or tube aversion, and those with high treatment burden; if she will request the HSE to examine its potential use within the national diabetes technology pathway; and if she will make a statement on the matter. [65091/25]